Drug Search Results
More Filters [+]

CART-30

Alternative Names: cart-30, cart30, cart 30, CAR.CD30, CD30-CAR
Latest Update: 2024-10-29
Latest Update Note: Clinical Trial Update

Product Description

anti-CD30 CAR T cells for CD30 positive Hodgkin's lymphoma and Non-Hodgkin's lymphoma (Sourced from: https://clinicaltrials.gov/ct2/show/NCT02259556)

Mechanisms of Action: CAR-T

Novel Mechanism: No

Modality: Cell Therapy

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Shanghai First Song Biotechnology Co., LTD
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for CART-30

Countries in Clinic: China

Active Clinical Trial Count: 1

Highest Development Phases

Phase 1: Relapsed/Refractory Lymphoma

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

CD20/CD30-CN-A1

P1

Recruiting

Relapsed/Refractory Lymphoma

2025-09-01

Recent News Events